Status
Conditions
About
This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk pregnancy of PE, SPB, and GDM in Vietnam.
Full description
This study is estimated to enroll 663 pregnant women with adverse pregnancy complications, including 221 cases of PE/eclampsia, 221 cases of SPB due to Preterm premature rupture of membranes (PPROM) or preterm labor, and 221 cases of GDM. Furthermore, the control group will enroll 442 participants, who are healthy pregnancies, ≥ 37 weeks of gestation. Study subjects who participate should meet the study inclusion and exclusion criteria:
As part of the protocol, demographic data, medical and family history, outcomes at delivery, and any relevant prior concomitant medication data will be recorded during follow-up visits. All participants are to be followed until birth delivery.
SAMPLE COLLECTION
The study end date of a participant is estimated within 7 months since her enrollment date.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
At recruitment, women with singleton pregnancies must fulfill the conditions:
Cases: diagnosis of Preeclampsia/eclampsia, Preterm premature rupture of membranes (PPROM)/preterm labor leading to SPB, and/or gestational diabetes mellitus.
Controls: healthy pregnancy at ≥ 37 weeks of gestation
History of undergoing non-invasive prenatal testing (NIPT) at 9-13 weeks 6 days of gestation at Gene Solutions Lab. NIPT report was at low-risk. No abnormal fetal and maternal conditions were confirmed at NIPT time.
NIPT blood sample is available according to post-test sample storage procedures at Gene Solutions Lab.
Consent to voluntarily participate in the study
Exclusion criteria
Loading...
Central trial contact
Sang H Sang, MSc, MD; VAN T Phan, MSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal